Crenolanib is a potent class III receptor tyrosine kinase inhibitor including PDGFRB, with minimal toxicity, whose therapeutic efficacy has already been validated through clinical trials in GIST and human acute myeloid leukemia. Here, PDGFRB is linked to gastrointestinal stromal tumor.